The HyRec-Trial, a multicenter study sponsored by the University of Erlangen Medical School and approved by the German Cancer Society, intends to enroll 59 patients. They will receive a combination of chemotherapy (5-FU/oxaliplatin), radiotherapy, and hyperthermia treatments using the BSD-2000 hyperthermia system.

Dr. Oliver Ott, associate professor of the department of radiation oncology, is the principal investigator of this phase I/II clinical study. The Universitätsklinikum Erlangen has been instrumental in establishing preoperative chemotherapy and radiation as the current standard of care for treating stage II and III rectal cancer. Other participating institutions include the Universitätsklinikum Munich Grosshadern and UMS Tübingen.

A randomized phase III clinical trial will be initiated if the study parameters are met. To date, published results of two randomized clinical trials have demonstrated that radiotherapy combined with chemotherapy and deep hyperthermia treatment can improve tumor response, local control, and survival rates in some patients with rectal cancer, according to BSD.

BSD Medical cleared to enter Russian market, August 28, 2012

BSD Medical launches MicroThermX tabletop in Europe, May 21, 2012

BSD Medical promotes new hyperthermia clinical study, May 8, 2012

BSD Medical nabs Swiss contract, February 18, 2010